Wedbush Issues Negative Forecast for Scholar Rock Earnings

Scholar Rock Holding Corporation (NASDAQ:SRRK) – Wedbush dropped their Q3 2025 earnings per share (EPS) estimates for Scholar Rock in a research report issued to clients and investors on Wednesday, August 6th. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share of ($0.70) for the quarter, down from their previous forecast of ($0.64). Wedbush has a “Outperform” rating and a $50.00 price target on the stock. The consensus estimate for Scholar Rock’s current full-year earnings is ($2.42) per share. Wedbush also issued estimates for Scholar Rock’s FY2025 earnings at ($2.98) EPS, Q1 2026 earnings at ($0.60) EPS, Q2 2026 earnings at ($0.52) EPS, Q3 2026 earnings at ($0.43) EPS, Q4 2026 earnings at ($0.31) EPS, FY2026 earnings at ($1.86) EPS, FY2027 earnings at ($0.36) EPS and FY2028 earnings at $0.89 EPS.

A number of other equities analysts also recently commented on the company. Lifesci Capital upgraded Scholar Rock to a “strong-buy” rating in a research report on Tuesday, June 3rd. BMO Capital Markets reduced their price objective on Scholar Rock from $57.00 to $45.00 and set an “outperform” rating on the stock in a research report on Thursday, August 7th. Cantor Fitzgerald started coverage on Scholar Rock in a research report on Thursday, July 17th. They set an “overweight” rating on the stock. Finally, Raymond James Financial set a $53.00 price objective on Scholar Rock and gave the stock a “strong-buy” rating in a research report on Wednesday, July 30th. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $45.14.

Scholar Rock Stock Performance

NASDAQ SRRK opened at $31.46 on Monday. The company has a market cap of $3.02 billion, a PE ratio of -10.81 and a beta of 0.48. The stock’s 50 day simple moving average is $35.78 and its 200-day simple moving average is $34.28. Scholar Rock has a 1-year low of $6.76 and a 1-year high of $46.98. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.33 and a quick ratio of 6.33.

Scholar Rock (NASDAQ:SRRK) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.32). During the same quarter in the prior year, the business earned ($0.60) earnings per share.

Institutional Investors Weigh In On Scholar Rock

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Alliancebernstein L.P. grew its stake in shares of Scholar Rock by 39.5% in the fourth quarter. Alliancebernstein L.P. now owns 79,350 shares of the company’s stock valued at $3,430,000 after buying an additional 22,480 shares in the last quarter. Wells Fargo & Company MN grew its stake in shares of Scholar Rock by 58.7% in the fourth quarter. Wells Fargo & Company MN now owns 38,590 shares of the company’s stock valued at $1,668,000 after buying an additional 14,274 shares in the last quarter. Invesco Ltd. grew its stake in shares of Scholar Rock by 1,292.8% in the fourth quarter. Invesco Ltd. now owns 312,161 shares of the company’s stock valued at $13,492,000 after buying an additional 289,748 shares in the last quarter. Legal & General Group Plc grew its stake in shares of Scholar Rock by 20.1% in the fourth quarter. Legal & General Group Plc now owns 61,790 shares of the company’s stock valued at $2,671,000 after buying an additional 10,321 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of Scholar Rock in the fourth quarter valued at $2,625,000. Hedge funds and other institutional investors own 91.08% of the company’s stock.

Insider Buying and Selling

In other Scholar Rock news, insider Mo Qatanani sold 24,066 shares of Scholar Rock stock in a transaction on Tuesday, July 8th. The stock was sold at an average price of $34.44, for a total value of $828,833.04. Following the sale, the insider owned 115,495 shares in the company, valued at $3,977,647.80. The trade was a 17.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jeffrey S. Flier sold 11,136 shares of Scholar Rock stock in a transaction on Wednesday, July 16th. The shares were sold at an average price of $40.02, for a total value of $445,662.72. Following the completion of the sale, the director owned 24,070 shares in the company, valued at $963,281.40. This represents a 31.63% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 93,654 shares of company stock valued at $3,101,811. 13.30% of the stock is currently owned by company insiders.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.